News articles about Sinovac Biotech (NASDAQ:SVA) have been trending somewhat positive on Tuesday, Accern Sentiment reports. Accern rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sinovac Biotech earned a coverage optimism score of 0.01 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.159247799664 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Sinovac Biotech (NASDAQ SVA) opened at $8.31 on Tuesday. The firm has a market capitalization of $473.26, a PE ratio of -830.17 and a beta of 0.13. Sinovac Biotech has a 52 week low of $4.60 and a 52 week high of $8.67.

Sinovac Biotech (NASDAQ:SVA) last released its quarterly earnings data on Wednesday, November 22nd. The biopharmaceutical company reported $0.08 earnings per share for the quarter. The firm had revenue of $31.37 million during the quarter.

Separately, BidaskClub raised Sinovac Biotech from a “hold” rating to a “buy” rating in a research note on Friday, November 3rd.

ILLEGAL ACTIVITY NOTICE: This report was first published by Marea Informative and is owned by of Marea Informative. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.mareainformativa.com/sinovac-biotech-sva-given-media-impact-score-of-0-01-updated-updated-updated/126172/.

Sinovac Biotech Company Profile

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.

Insider Buying and Selling by Quarter for Sinovac Biotech (NASDAQ:SVA)

Receive News & Ratings for Sinovac Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech and related companies with MarketBeat.com's FREE daily email newsletter.